bcl-2 Expression in plasma cells from neoplastic gammopathies and reactive plasmacytosis: A comparative study

Haematologica

Volumn 83, Issue 4, 1998, Pages 298-304

  Miguel García, Alicia ^a,e   Orero, Teresa ^a   Matutes, Estela ^b   Carbonell, Francisco ^c   Miguel Sosa, Amparo ^a   Linares, Mariano ^a   Tarín, Fabian ^a   Herrera, Magdalena ^d   García Talavera, Juan ^d   Carbonell Ramón, Felix ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c Valencia Transfusion Centre   (Spain)

^d HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^e Centro de Transfusión de Valencia   (Spain)

Author keywords

Apoptosis; bcl 2; Monoclonal gammopathy of unknown significance; Multiple myeloma; Plasma cells

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY KI 67; PROTEIN BCL 2;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CLINICAL FEATURE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PLASMA CELL; PLASMACYTOSIS; PROTEIN EXPRESSION; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; LYMPHOCYTOSIS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PARAPROTEINEMIAS; PLASMA CELLS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0031957034     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Fukura S, Rowley JD, Variokojis D, Golomb HM. Chromosome abnormalities in poorly differentiated lymphocytic lymphoma. Cancer Res 1979; 39:3119-28.
2. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 1984; 226:1097-9.
3. Ngan BY, Chen-levy Z, Weiss LM, Warke RA, Cleary ML. Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t(14;18) translocation. N Engl J Med 1988; 318:1638-44.
4. Pezella F, Tse AGD, Cordell JL, Pulford KAF, Gatter KC, Mason DY. Expression of the bcl-2 protein is not specific for the 14;18 chromosomal translocation. Am J Pathol 1990; 137:225-32.
5. Hockenberry DM, Zutter M, Hickey W, Nahm M, Korsmeyer S. bcl-2 protein is topographically restricted in tissues by apoptotic cell death. Proc Natl Acad Sci USA 1991; 88:6961-5.
6. Pezella F, Gatter K. What is the value of bcl-2 protein detection for the histopathologist? Histopatology 1995; 26:89-93.
7. Koersmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992; 80:879-86.
8. McDonell TJ, Korsmeyer SJ. Progression from lymphoid hyperplasia to high grade malignant lymphoma in mice transgenic for the t(14;18). Nature 1991; 349: 254-6.
9. Linette GP, Hess JL, Sentman CL, Korsmeyer SJ. Diffuse malignant T cell lymphoma in lck-bcl-2-trasgenic mice. Blood 1995; 86:1255-60.
10. Yang E, Korsmeyer J. Molecular thanaptosis: a discourse on the bcl-2 family and cell death. Blood 1996; 88:386-401.
11. Merup M, Spasokoukotskaja T, Einhorn S, Smith E, Garthon G, Juliusson G. Bcl-2 rearrangements with breakpoints in both vcr and mbr in non-Hogkin's lymphoma and chronic lymphocytic leukaemia. Br J Haematol 1996; 92:647-52.
12. Nuñez G, London Y, Hockenberry D, Alexander M, Mckearn JP, Korsmeyer SJ. Deregulated bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol 1990; 144:3602-10.
13. Campos L, Roualt JP, Sabido O, et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993; 81:3091-6.
14. Porwit-McDonald A, Ivory K, Wilkinson S, Wheatley K, Wong L, Janossy G. bcl-2 protein expression in normal bone marrow precursors and in acute leukemia. Leukemia 1995; 9:1191-8.
15. Coustan-Smith E, Kitanaka A, Pui CH, et al. Clinical relevance of bcl-2 overexpression in childhood acute lymphoblastic leukemia. Blood 1996; 87:1140-6.
16. Maung ZT, McLean M, Reid MM, et al. The relationship between bcl-2 expression and response to chemotherapy in acute leukaemia. Br J Haematol 1994; 8:105-9.
17. Zutter M, Hockenbery D, Silverman G, Korsmeyer J. Immunolocalization of the bcl-2 protein within hematopoietic neoplasms. Blood 1991; 78:1062-88.
18. Pezella F, Jones M, Ralfkier E, Ersboll J, Gatter KC, Mason DY. Evaluation of bcl-2 protein expression and 14;18 traslocation as prognostic markers in follicular lymphoma. Br J Cancer 1992; 65:87-92.
19. Piris MA, Pezella F, Martinez-Montero JC, et al. p53 and bcl-2 expression in high grade B-cell lymphomas: correlation with survival time. Br J Cancer 1994; 69:337-41.
20. Hermine O, Haioun C, Lepage E, et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Blood 1996; 87:265-72.
21. Hill M, Kenneth A, McLenan A, et al. Prognostic significance of bcl-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgking lymphoma: a British National Lymphoma Investigation study. Blood 1996; 88:1046-51.
22. Schena M, Larsson LG, Gottardi D, et al. Growth and differentiation associated expression of bcl-2 in B chronic lymphocytic leukemia cells. Blood 1992; 79:2981-9.
23. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy induced apoptosis in a human leukemia cell line. Blood 1993; 81:151-7
24. Pettersson M, Jernberg-Wicklund H, Larsson LG, et al. Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells. Blood 1992; 79:495-502.
25. Hamilton MS, Barker HF, Ball J, Drew M, Abbot SD, Franklin IM. Normal and neoplastic plasma cells express the bcl-2 antigen. Leukemia 1991; 5:768-71.
26. Durie BGM, Mason DY, Giles F, et al. Expression of the bcl-2 oncogene protein in multiple myeloma, [abstract]. Blood 1990; 76 (Suppl 1):374a.
27. Tu Y, Xu FH, Liu J, Vescio R, Berenson J, Fady C, Lichtenstein A. Upregulated expression of bcl-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide and hydrogen peroxide. Blood 1996; 88: 1805-12.
28. Kyle RA, Lust JA. Monoclonal gammopathy of undeterminated significance. Semin Hematol 1989; 26: 176-200.
29. Chronic Leukemia-Myeloma Task Force, National Cancer Institute proposed guidelines for protocol studies. II. Plasma cell myeloma. Cancer Chemother Rep 1973; 4:145-58.
30. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975; 36:842-54.
31. Cordell JL, Fallini B, Erber WH, et al. Immunoenzimatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal antialkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984; 32:219-22.
32. Mason DY, Cordell JL, Abdullazid Z., Natem M, Bordanare G. Preparation of peroxidase-antiperoxidase (PAP) complexes for immunohistological labelling of monoclonal antibodies. J Histochem Cytochem 1982; 30:1114-22.
33. Miguel-García A, Matutes E, Tarín F, et al. Circulating Ki-67 positive lymphocytes in multiple myeloma and bening monoclonal gammopathy. J Clin Pathol 1995; 48:835-9.
34. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. JAMA 1958; 53:475-81.
35. Mantel N. Evaluation of survival data and two new rank order statistics arising in its considerations. Cancer Chemoter Rep 1966; 50:163-70.
36. Schena M, Larsson LG, Gottardi D, et al. Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. Blood 1992; 11: 2981-9.
37. Wilson W, Teruya-Feldstein J, Fest T, et al. Relationship of p-53, bcl-2 and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood 1997; 89:601-9.
38. Wolowiec D, Mekki Y, Ffrench P, et al. Differential expression of cell proliferation regulatory proteins in B-and T-lineage acute lymphoblastic leukaemias. Br J Haematol 1996; 95:518-23.
39. Winter JN, Andersen J, Reed JC, et al. bcl-2 expression correlates with lower proliferative activity in non-Hodking's lymphoma (NHL), an ECOG study [abstract]. Blood 1995; 86(Suppl 1):1351 a.
40. Kramer MHH, Hermans J, Parker J, et al. Clinical significance of bcl-2 and p-53 protein expression in diffuse large B cell lymphoma: a population based study. J Clin Oncol 1996; 14:2131-8.
41. Pepper C, Bentley P, Hoy T. Regulation of clinical chemoresistance by bcl-2 and bax oncoproteins in B cell chronic lymphocytic leukaemia. Br J Haematol 1996; 95:513-7.
42. Ong F, Nieuwkoop JA, Groot-Swings GMJS, et al. Bcl-2 protein expression is not related to short survival in multiple myeloma. Leukemia 1995; 9:1282-4.